1616345-45-9
Chemical Structure
Monomethyl fumarate-d5
- CAS No.: 1616345-45-9
- Formula:C5HD5O4
- Molecular Weight:135.13
IUPAC Name: (E)-4-(methoxy-d3)-4-oxobut-2-enoic-2,3-d2 acid
InChIKey: NKHAVTQWNUWKEO-PWYLTMEHSA-N
SMILES: OC(/C([2H])=C([2H])/C(OC([2H])([2H])[2H])=O)=O
Biological Activity: Monomethyl fumarate-d5 is deuterium labeled Monomethyl fumarate (HY-103252)[1]. Monomethyl fumarate, an active metabolite of Dimethyl fumarate (DMF) (HY-17363), is a potent GPR109A agonist. Monomethyl fumarate has the potential for multiple neuroprotective pathways and other models of retinal disease[2][3][4].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Monomethyl fumarate-d5 | Monomethyl fumarate-d5 is deuterium labeled Monomethyl fumarate (HY-103252). Monomethyl fumarate, an active metabolite of Dimethyl fumarate (DMF) (HY-17363), is a potent GPR109A agonist. Monomethyl fumarate has the potential for multiple neuroprotective pathways and other models of retinal disease. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Monomethyl fumarate (Standard) | ≥98% | Monomethyl fumarate (Standard) is the analytical standard of Monomethyl fumarate. This product is intended for research and analytical applications. Monomethyl fumarate, an active metabolite of Dimethyl fumarate (DMF), is a potent GPR109A agonist. Monomethyl fumarate has the potential for multiple neuroprotective pathways and other models of retinal disease. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Monomethyl fumarate-d2 | 98.19% | Monomethyl fumarate-d2 is a deuterium labeled Monomethyl fumarate (HY-103252). Monomethyl fumarate, an active metabolite of Dimethyl fumarate (DMF) (HY-17363), is a potent GPR109A agonist. Monomethyl fumarate has the potential for multiple neuroprotective pathways and other models of retinal disease. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Monomethyl fumarate-d3 | 99.01% | Monomethyl fumarate-d3 is a deuterium labeled Monomethyl fumarate (HY-103252). Monomethyl fumarate, an active metabolite of Dimethyl fumarate (DMF) (HY-17363), is a potent GPR109A agonist. Monomethyl fumarate has the potential for multiple neuroprotective pathways and other models of retinal disease. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Monomethyl fumarate | 99.95% | Monomethyl fumarate, an active metabolite of Dimethyl fumarate (DMF), is a potent GPR109A agonist. Monomethyl fumarate has the potential for multiple neuroprotective pathways and other models of retinal disease. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
-
Similarity Score 1.00
HY-W705769(Z)-4-(Methoxy-d3)-4-oxobut-2-enoic acid -
Similarity Score 0.87
HY-W019696Monoethyl fumarate -
Similarity Score 0.87
HY-W704787Monoethyl fumarate-d5 -
Similarity Score 0.86
HY-W392912AMethyl trans-4-oxo-2-pentenoate -
Similarity Score 0.86
HY-W127447Maleate trihydrate sodium -
Similarity Score 0.84
HY-17363Dimethyl fumarate -
Similarity Score 0.82
HY-W015883RFumaric acid (Standard) -
Similarity Score 0.82
HY-W015883SFumaric acid-13C4 -
Similarity Score 0.82
HY-W015883S1Fumaric acid-13C2 -
Explore the MedChemAI to find more analogs
References
- [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. [Content Brief]
- [2]. Tang H, et al. The psoriasis drug monomethylfumarate is a potent nicotinic acid receptor agonist. Biochem Biophys Res Commun. 2008 Oct 31;375(4):562-5. [Content Brief]
- [3]. Jiang D, et al. Monomethyl Fumarate Protects the Retina From Light-Induced Retinopathy. Invest Ophthalmol Vis Sci. 2019 Mar 1;60(4):1275-1285. [Content Brief]
- [4]. Sghaier R, et al. Dimethyl fumarate and monomethyl fumarate attenuate oxidative stress and mitochondrialalterations leading to oxiapoptophagy in 158N murine oligodendrocytes treated with 7β-hydroxycholesterol. J Steroid Biochem Mol Biol. 2019 Nov;194:105432. [Content Brief]